LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer

• Published in: Scientific reports 2018-01, Vol.8 (1), p.73-18, Article 73
• Main Authors: Boulding, T., McCuaig, R. D., Tan, A., Hardy, K., Wu, F., Dunn, J., Kalimutho, M., Sutton, C. R., Forwood, J. K., Bert, A. G., Goodall, G. J., Malik, L., Yip, D., Dahlstrom, J. E., Zafar, A., Khanna, K. K., Rao, S.
• Format: Article
• Language: English
• Subjects: 13/1; 13/106; 13/109; 13/31; 13/51; 13/89; 13/95; 14/19; 14/63; 38/61; 38/77; 631/67/1347; 631/80; 64/60; Breast cancer; Cancer therapies; Chemotherapy; Chromatin; Epigenetics; Gene expression; Humanities and Social Sciences; Immune response; Kinases; Lysine; Macrophages; Mesenchyme; Metastases; multidisciplinary; Phosphorylation; Protein kinase C; Science; Science (multidisciplinary); Serine; Stem cells; Treatment resistance; Tumor microenvironment; Tumors
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-017-17913-x

Complex regulatory networks control epithelial-to-mesenchymal transition (EMT) but the underlying epigenetic control is poorly understood. Lysine-specific demethylase 1 (LSD1) is a key histone demethylase that alters the epigenetic landscape. Here we explored the role of LSD1 in global epigenetic regulation of EMT, cancer stem cells (CSCs), the tumour microenvironment, and therapeutic resistance in breast cancer. LSD1 induced pan-genomic gene expression in networks implicated in EMT and selectively elicits gene expression programs in CSCs whilst repressing non-CSC programs. LSD1 phosphorylation at serine-111 (LSD1-s111p) by chromatin anchored protein kinase C-theta (PKC-θ), is critical for its demethylase and EMT promoting activity and LSD1-s111p is enriched in chemoresistant cells in vivo . LSD1 couples to PKC-θ on the mesenchymal gene epigenetic template promotes LSD1-mediated gene induction. In vivo , chemotherapy reduced tumour volume, and when combined with an LSD1 inhibitor, abrogated the mesenchymal signature and promoted an innate, M1 macrophage-like tumouricidal immune response. Circulating tumour cells (CTCs) from metastatic breast cancer (MBC) patients were enriched with LSD1 and pharmacological blockade of LSD1 suppressed the mesenchymal and stem-like signature in these patient-derived CTCs. Overall, LSD1 inhibition may serve as a promising epigenetic adjuvant therapy to subvert its pleiotropic roles in breast cancer progression and treatment resistance.